Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781975 · ClinicalTrials.gov registry record · Phase 2
Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT01781975 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 67 participants.
The verdict
NCT01781975, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia with current technology, and thus they are at risk for devastating long-term complications. This phase II study is designed to evaluate the safety and efficacy of imatinib mesylate as a novel therapy for new-onset T1DM. Imatinib is a first-in-class tyrosine kinase inhibitor. This study will explore the potential role of short-term therapy with imatinib to induce tolerance and possibly lead to a durable long-term remission of T1DM.
Interventions
- DRUG Imatinib Mesylate
- DRUG Placebo (For imatinib mesylate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781975
The ClinicalTrials.gov registry entry for NCT01781975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imatinib Mesylate is the first listed.
NCT01781975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01781975 about?
NCT01781975 is a clinical study titled "Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus". Type 1 diabetes mellitus (T1DM) results from the autoimmune destruction of insulin-producing ß cells. Although exogenous insulin is widely available, it is not possible for affected individuals to consistently achieve euglycemia with current technology, and thus they are at risk for devastating long...
What is the current status of trial NCT01781975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2014-01. Estimated completion is 2018-05.
What interventions are being tested in trial NCT01781975?
The interventions under investigation include: Imatinib Mesylate (DRUG), Placebo (For imatinib mesylate) (DRUG).
Who is sponsoring clinical trial NCT01781975?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.